Xu Jinghe,Deputy Commissioner of CNDA,attends the China US Conference on the Development and Evaluation of Oncology Drugs

On the morning of July 2,2018,Xu Jinghe,Deputy Commissioner of the National Drug Administration of China(CNDA),attended the China US Exchange for Cancer Drug Development and Evaluation held jointly by the CNDA and the US FDA.

The CNDA Center for Drug Evaluation(CDE) introduced the priority review of China's new antitumor drugs,and the US FDA Oncology Center of Excellence(OCE) has introduced the regulatory work of FDA in the novel anti-cancer drugs,expediting product development,listing and approving.

China US both sides discussed and exchanged experiences on the regulation of anti-cancer drugs.The relevant departments and subordinate units of the CNDA and more than 130 staff members of drug regulatory agencies in some provinces and municipalities participated.

Prior to the exchange meeting,Xu Jinghe met with Dr. Richard Pazdur(M.D.),the director of the FDA's Oncology Center of Excellence (OCE).
From CFDA website